Back

Long-term efficacy of endotype-based drug therapy on quality of life and symptom management in coronary vasomotion disorders

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in coronary artery disease (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mrs Leonie Saccardi

Robert Bosch Hospital, Stuttgart (Germany)

3 More presentations in this session

Presentation thumbnail
ACEi/ARB treatment in patients with myocardial infarction and preserved left ventricular ejection fraction does not confer a benefit: a target trial emulation
Doctor A. Humphreys (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Spironolactone and coronary atherosclerotic plaque modulation: insights from a serial coronary computed tomography angiography cohort study
Doctor J. Zhang (Chengdu, CN)
Abstract Slides Video
Presentation thumbnail
Heparin pretreatment in patients with ST-segment elevation myocardial infarction: a meta-analysis
Doctor L. Siega Vignut (Trieste, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in coronary artery disease (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Improvement of symptoms and quality of life in patients with coronary vasomotion disorders by endotype-based drug therapy
thumbnail
Congress Presentation
Targeted medical treatment based on specific endotype defined by intracoronary physiology testing leads to rapid improvement of quality of life in symptomatic patients with INOCA
thumbnail
Congress Presentation
Long-term outcomes of patients with ischemia and no obstructive coronary artery disease (INOCA) - a systematic review and meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources